Funding
Strategic · Biotech

Insilico Medicine receives $5m in strategic financing

Menarini Group, Eli Lilly, Tencent and Temasek participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Insilico Medicine received $5 million in strategic financing on February 3. Participants included Menarini Group, Eli Lilly, Tencent and Temasek. The company develops AI-driven drug-discovery technology and oncology treatments.

Funding history

Strategic · This round$5M

Sources

  1. Insilico Medicineprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related